Viking Therapeutics: Measured Progress In Key Trials Amid Rising R&D Costs (NASDAQ:VKTX)

Caucasian nurse hands showing measuring tape

Wirestock/iStock via Getty Images


Viking Therapeutics (NASDAQ:VKTX) is a clinical-stage biotech firm working on treatments for metabolic and endocrine issues. Their main drug, VK2809, is a thyroid hormone receptor beta agonist for non-alcoholic steatohepatitis (NASH), showing good tolerability in Phase 2b

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *